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RosaitDorfman disease is an uncommon disortder featured by histiocytic proliferation in the lymph nodes, clinically presenting as lymphadet
nopathy and/or extranodal involvement in onetfourth 
to onetthird of cases. Being a benign disorder, it needs 
to be differentiated from malignant causes especially 
lymphomas. The diagnosis comes from histopathology 
and the majority require no treatment.
CASE
A 30tyeartold woman presented with progressive rightt
sided nasal blockade and protrusion of the right eye of 
2 years duration. The disease was accompanied by prot
gressive diminution of vision on the right side for the 
previous 6 months. Prior to this, the patient had been 
complaining of bilateral nasal discharge for ten years, 
for which she had undergone nasal surgery twice, once 
in 2002 and again in 2006, the records of which she had 
lost. She denied any history of local pain, fever, weight 
loss or night sweats. There was no history of diabetes 
mellitus, tuberculosis or hypertension.
Examination revealed pallor, right eye proptosis with 
slight restriction of ocular movements medially and a 
visual acuity of 6/12 with normal pupillary reflexes and 
a fleshy nasal mass filling the right cavity, completely 
pushing the nasal septum to left side. The pharynx 
was clear. There was no fever, lymphadenopathy or ort
ganomegaly. Investigations revealed a hemoglobin of 
5.9 g/dL, with a normal total leukocyte count, differt
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rosai-Dorfman disease, also known as sinus histiocytosis with massive lymphadenopathy, is a benign 
indolent disorder, characterized by enlarged lymph nodes filled with histiocytes. Extranodal involvement 
is uncommon. the disease rarely affects the nose and paranasal sinuses. We report a case that presented 
with a right nasal mass, extending into all the paranasal sinuses and right orbit without any accompany-
ing lymphadenopathy. Because of the absence of lymphadenopathy it posed a diagnostic challenge until 
the pathology was confirmed on histopathological examination.
ent leukocyte count, and platelets. A peripheral smear 
showed microcytic, hypochromic anemia, possibly iron 
deficiency anemia. The erythrocyte sedimentation rate 
was 32 mm the first hour. Blood glucose, renal function 
tests, liver function tests, and uric acid were normal. 
Chest xtray, echocardiography, and CT abdomen were 
also normal. Nontcontrast CT of the paranasal sinuses 
revealed a heterogeneous mass arising in the right nasal 
cavity, extending into all the sinuses and also eroding 
the medial walls of both the orbits. The lobulated lesion 
in the right orbit was abutting the optic nerve, the right 
medial and inferior recti muscles and causing lateral 
displacement of the globe. The lesion also extended into 
the right buccal space, the infratemporal fossa and soft 
tissue of the cheek on the right side (Figure 1).
For the mass lesion, the patient underwent endot
scopic nasal mass excision under general anesthesia. A 
righttsided nasal mass that filled the entire nasal cavity 
was debulked. The mass engulfed the nasal septum and 
all the sinuses bilaterally. Disease was cleared from the 
sinuses and part of the nasal septum was removed. The 
posttoperative period was uneventful. Orbital mass cleart
ance was not attempted, but planned for a later date.
The histopathological examination revealed a dense 
mixed inflammatory cell infiltrate, rich in plasma cells 
and histiocytes, which showed emperipolesis. No grant
uloma or necrosis was seen. Stain for fungus was negat
tive and on immunohistochemistry, the histiocytic cells 
were positive for St100. Overall features were consist
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tent with RosaitDorfman disease (Figure 2a, 2b). The 
patient was given CVP (cyclophosphamide, vincristine, 
prednisolone) therapy, concurrent with iron.  
DISCUSSION
In 1969 two pathologists, Juan Rosai and Ronald 
Dorfman, reported a distinct histiocytic disorder in 
young black males who presented with bilateral, paint
less, massive cervical lymphadenopathy that in most 
instances was associated with fever, anemia, neutrot
philia, an elevated erythrocyte sedimentation rate, and 
polyclonal gammopathy.1 They named it sinus histiot
cytosis with massive lymphadenopathy and it was later 
renamed RosaitDorfman disease.1 
The disease has a worldwide distribution and can 
occur at any age, although it is common in adults. The 
maletfemale ratio is 2:1. Painless lymphadenopathy is 
the most common presentation and involves the cervit
cal region in up to 90% of patients.2 Other locations 
such as inguinal (26%), axillary (24%) and mediastinal 
lymph nodes (15%) are also reported to be involved.2 
Extranodal disease is seen in 25% to 43% of patients, 
with or without associated lymphadenopathy.2 The 
most common extranodal sites, in decreasing order of 
frequency, are the skin, nasal cavity and paranasal sit
nuses, eyelid, orbit, bone, salivary gland and the central 
nervous system. Hepatosplenomegaly, unlike in other 
histiocytic disorders, is uncommon.2 Laboratory findt
ings include hematological abnormalities such as nort
mocytic or microcytic anemia, hemolytic anemia, an 
elevated erthrocyte sedimentation rate and polyclonal 
hypergammaglobulinemia.2
The etiology of the disease remains obscure, but 
two hypotheses have been proposed: a disturbance in 
cell mediated immunity, and a focus of infection due 
to EpsteintBarr virus, Klebsiella, Brucella or human 
herpesvirust6. According to Foucar et al3 the most fret
quent otorhinolaryngologic manifestations are found in 
the nasal cavity (50%), followed by the pharynx (25%), 
the paranasal sinuses (18.7%) and the trachea (6.3%).
In the orbit, the most commonly affected sites are the 
soft tissue (84.6%) and eyelids (45.5 %), which manifest 
as exophthalmus (53.8%), clouding of vision, conjunct
tival infiltration, diplopia, increased or reduced lacrit
mation, and slight ocular irritation.4 The diagnosis of 
RosaitDorfman disease is made on the basis of clinical 
suspicion and confirmed by histopathologic examinat
tion. Histopathologic findings include lymphoid aggret
gates intercalated with areas consisting of histiocytes, 
lymphocytes, and plasma cells. The hallmark of Rosait
Dorman disease is lymphophagocytosis or emperipolet
sis, wherein the viable lymphocytes are located in wellt
Figure 1. Heterogenous mass in both nasal cavities, maxillary sinuses and the right orbit 
causing proptosis (non-contrast CT scan).
Figure 2a. Inflammatory infiltrate, rich in histiocytes showing 
emperipolesis (hematoxylin and eosin, 40×). 
Figure 2b. S-100 positive histiocytes (±immunohistochemistry 
with S-100, 20×). 
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defined cytoplasmic vacuoles of intact histiocytes. The 
involved histiocytes are activated macrophages with 
features of phagocytic cells as well as immune accest
sory cells and thus express St100 protein, HAM 56, 
α1 antitrypisn, α1 chymotrypsin, lysozyme, Mac 387, 
Kit1 (CD 30, BertH2), but are negative for CD1a.5 
The histological differential diagnosis includes hemot
phagocytic syndromes, storage disorder, inflammatory 
lesions, necrobiotic xanthogranuloma and lymphoretict
ular malignancies.6 The presence of benign histiocytes 
with emperipolesis, an absence of cellular atypia, the 
immunohistochemical profile, and associated clinical 
features distinguish RosaitDorfman disease from other 
similar disorders. 
The clinical course of RosaitDorfman disease is 
chronic and variable with the majority achieving ret
mission in the long run. The ideal treatment for Rosait
Dorfman disease is as yet unestablished. Only about 
50% of patients with RosaitDorfman disease need some 
form of treatment.7 Management options include obt
servation for mild manifestations with no cosmetic or 
functional abnormality, surgical excision or debulking 
for lesions in surgically accessible locations, systemic 
corticosteroids, chemotherapy (which may include vint
cristine, 6MP, methotrexate, alkylating agents) or radiot
therapy in patients with severe symptoms or where vital 
organ function is compromised.8 The treatment of ort
bital manifestations of RosaitDorfman disease aims to 
control the functional and cosmetic abnormalities. The 
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treatment may include surgery, systemic corticosteroids, 
chemotherapy or radiotherapy for massive or recurrent 
orbital disease or significant residual lesion following 
surgical debulking. Chemotherapy has also been used 
to relieve sighttthreatening optic nerve compression.3 
Goldberg et al9 treated a patient with RosaitDorfman 
disease with compressive optic neuropathy with a comt
bination of cyclophosphamide, vincristine and prednisot
lone and found excellent results with 6 months therapy. 
Komp7 also showed the superiority of CVP over other 
chemotherapeutic regimens. Horneff et al10 demonstratt
ed the efficacy of methotrexate and 6tmercaptopurine 
(6tMP) in a 3tyeartold girl with cervical lymphadenopat
thy. However, Pulsoni et al11 disfavored chemotherapy. 
Jubran et al12 treated one child with rituximab after a 
suboptimal response with steroids, methotrexate and 6t
MP and showed complete resolution of lymphadenopat
thy. Jabali13 cured a patient with chemotherapy with no 
reccurrence of the disease after 5.5 years.
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